Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaad.2004.01.030 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immunotherapy of Human Melanoma: Past, Present, Future.
Curr Med Chem
March 2024
Department of Anatomy, School of Medicine, Infectious Diseases Research Center, Gonabad University of Medical Sciences, Gonabad, Iran.
Immunotherapy with immune checkpoint inhibitors (ICIs) is a promising therapeutic schedule in advanced solid cancers. In this review, clinical trials from highly reputable journals are interpreted for safety and efficacy evaluation of the common anti-programmed death-1 (PD-1) inhibitor nivolumab and/or the most known anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) inhibitor ipilimumab in advanced melanoma. Current progress in the field of melanoma immunotherapy is the focus of this review.
View Article and Find Full Text PDFClinical and molecular overview of immunotherapeutic approaches for malignant skin melanoma: Past, present and future.
Crit Rev Oncol Hematol
June 2023
Institute for Biodiversity and Sustainability (NUPEM), Federal University of Rio do Janeiro, Macaé, RJ, Brazil. Electronic address:
Traditional therapeutic approaches for malignant melanoma, have proved to be limited and/or ineffective, especially with respect to their role in improving patient survival and tumor recurrence. In this regard, immunotherapy has been demonstrated to be a promising therapeutic alternative, boosting antitumor responses through the modulation of cell signaling pathways involved in the effector mechanisms of the immune system, particularly, the so-called "immunological checkpoints". Clinical studies on the efficacy and safety of immunotherapeutic regimens, alone or in combination with other antitumor approaches, have increased dramatically in recent decades, with very encouraging results.
View Article and Find Full Text PDFGene expression profiling in melanoma: past results and future potential.
Future Oncol
March 2019
Department of Plastic Surgery, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
The field of melanoma oncology is rapidly evolving with advances in detection, staging and treatment. There is heterogeneity in all stages of melanoma where some patients fare better than others for reasons currently unknown and it is sometimes unclear which patients warrant closer surveillance, multidisciplinary care, increased imaging, more aggressive surgery or adjuvant therapy. Early studies have shown the predictive ability of gene expression profiling (GEP) and institutions that have adopted GEP for melanoma treatment have demonstrated changes in practice patterns and patient management.
View Article and Find Full Text PDFMelanoma, past severe sunburns and multiple solar lentigines of the upper back and shoulders.
Dermatology
June 2008
Service de Dermatologie, Hôpital Robert-Debré, Reims, France.
Background: Multiple solar lentigines of the upper back and shoulders (MSLBS) have recently been demonstrated as being associated with intense sunburns in the past.
Objective: To determine the prevalence of MSLBS among patients with cutaneous melanoma.
Methods: Thisprevalence study was conducted prospectively from October 2003 to November 2004 in a single department of dermatology (Reims University Hospital, north of France).
Cutaneous melanoma--past, present, and future.
J Am Acad Dermatol
July 2004
Department of Dermatology, Yale University School of Medicine, New Haven, CT 06520, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!